Key result
Mesenchymal stem cells reduce foam cell formation and inflammatory markers in rats with atherosclerosis.
Why the study?
Smooth muscle cells play a central role in atherosclerosis development, prompting evaluation of mesenchymal stem cell therapy to replace neointimal smooth muscle cells and improve atherosclerotic lesions.
Does CD34+ stem cell therapy improve atherosclerotic lesions and inflammatory markers in rats with experimentally induced atherosclerosis?
Does CD34+ stem cell therapy improve atherosclerotic lesions and inflammatory markers in rats with experimentally induced atherosclerosis?
Stem cell therapy significantly replaced neointimal smooth muscle cells and decreased adhesion molecules and inflammatory markers in an experimental rat model of atherosclerosis.
Hypothesis-generating for mesenchymal stem cell effects in rat atherosclerosis; human trials needed before clinical translation.
Smooth muscle cells (SMCs) are currently considered a central pivotal player in pathogenesis and development of atherosclerotic lesions. As consequence of vascular injury, SMCs migrate from the tunica media into the tunica intima layers where they contribute to neointimal formation by converting into foam cells and producing pro-inflammatory and oxidative stress markers. We targeted the replacement of neointimal SMCs by using the mesenchymal stem cells (MSCs) therapy in experimentally induced atherosclerosis in an attempt to improve the atherosclerotic lesion and its concomitant complications. Rats were divided into 4 groups (n=20). Control group: rats kept on a standard chow diet; atherosclerotic group: rats received the atherogenic diet; stem cells-treated group: rats were injected with CD34+ stem cells (6×106 cells in 0.5 mL PBS in rat tail vein) and maintained on the atherogenic diet; and resveratrol-treated group: rats were supplemented orally with resveratrol at a dose level 3 mg/kg per day and the atherogenic diet. After 12 weeks, rats were euthanized, blood samples were collected for separation of serum, and abdominal aortas were excised for further biochemical, molecular, and histopathological investigations. We used resveratrol, the well-established anti-atherosclerotic drug, as a benchmark to assess the efficacy of stem cell therapy. MSCs treatment revealed significant amelioration in both histopathological and biochemical patterns as evidenced by decreased foam cells formation, ICAM-1, VCAM, M-CSF, iNOS, COX-2, and TNF-α. We concluded that MSCs therapy significantly replaced the neointimal SMCs and decreased adhesion molecules as well as the oxidative and inflammatory markers in atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Hashem et al. (2021) studied Experimentally induced atherosclerosis (n=80). CD34+ stem cells vs. Atherogenic diet alone and resveratrol (3 mg/kg per day) was evaluated on Histopathological and biochemical patterns including foam cells formation, ICAM-1, VCAM, M-CSF, iNOS, COX-2, and TNF-α. Mesenchymal stem cell therapy significantly decreased foam cell formation, adhesion molecules, and inflammatory markers in rats with experimentally induced atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: